FOLD Amicus Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

FOLD [NASD]

Amicus Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.30	Insider Own	1.00%	Shs Outstand	256.97M	Perf Week	0.00%
Market Cap	3.19B	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-17.91%	Shs Float	229.91M	Perf Month	7.37%
Income	-325.00M	PEG	-	EPS next Q	-0.26	Inst Own	-	Short Float	14.05%	Perf Quarter	36.05%
Sales	208.70M	P/S	15.30	EPS this Y	21.10%	Inst Trans	3.90%	Short Ratio	9.43	Perf Half Y	20.36%
Book/sh	1.57	P/B	8.08	EPS next Y	23.60%	ROA	-38.40%	Target Price	17.95	Perf Year	12.51%
Cash/sh	1.35	P/C	9.42	EPS next 5Y	-1.00%	ROE	-64.10%	52W Range	6.25 - 13.39	Perf YTD	30.18%
Dividend	-	P/FCF	-	EPS past 5Y	-9.90%	ROI	-55.10%	52W High	-5.30%	Beta	1.28
Dividend %	-	Quick Ratio	4.30	Sales past 5Y	172.00%	Gross Margin	88.30%	52W Low	102.88%	ATR	0.66
Employees	584	Current Ratio	4.40	Sales Q/Q	77.90%	Oper. Margin	-	RSI (14)	60.06	Volatility	6.14% 5.50%
Optionable	Yes	Debt/Eq	0.37	EPS Q/Q	38.60%	Profit Margin	-	Rel Volume	0.67	Prev Close	12.48
Shortable	Yes	LT Debt/Eq	0.37	Earnings	May 07 BMO	Payout	-	Avg Volume	3.43M	Price	12.68
Recom	1.70	SMA20	5.33%	SMA50	14.53%	SMA200	29.17%	Volume	2,316,788	Change	1.64%

Feb-04-20

Resumed

Cantor Fitzgerald

Overweight

$19 → $20

Nov-12-19

Reiterated

H.C. Wainwright

Buy

$18 → $20

Jun-17-19

Initiated

H.C. Wainwright

Buy

$18

Jun-05-19

Reiterated

Cantor Fitzgerald

Overweight

$20 → $19

Apr-05-19

Initiated

Janney

Buy

Jan-30-19

Initiated

Cantor Fitzgerald

Overweight

$20

Oct-29-18

Initiated

Citigroup

Neutral

$12

Aug-17-18

Downgrade

Chardan Capital Markets

Buy → Neutral

$18 → $15

Oct-06-17

Resumed

Goldman

Neutral

Sep-13-17

Reiterated

Chardan Capital Markets

Buy

$17.50 → $16.50

Aug-10-17

Reiterated

Chardan Capital Markets

Buy

$12.50 → $17.50

Jan-24-17

Upgrade

Robert W. Baird

Neutral → Outperform

$7 → $10

May-18-16

Initiated

BofA/Merrill

Buy

$10

Apr-14-16

Initiated

Robert W. Baird

Neutral

Apr-12-16

Reiterated

Chardan Capital Markets

Buy

$10 → $15

Sep-16-15

Downgrade

Chardan Capital Markets

Buy → Neutral

$17

Jun-16-15

Reiterated

Chardan Capital Markets

Buy

$14 → $17.50

May-29-15

Initiated

Chardan Capital Markets

Buy

$14

Dec-20-12

Reiterated

Canaccord Genuity

Buy

$11 → $6

Dec-20-12

Downgrade

Capstone Investments

Buy → Hold

May-21-20 02:25PM	Edited Transcript of FOLD earnings conference call or presentation 7-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-19-20 09:47AM	Billionaire Steven Cohen Bets Big on These 3 Stocks TipRanks
May-10-20 09:50AM	Analysts Are Updating Their Amicus Therapeutics, Inc. (NASDAQ:FOLD) Estimates After Its First-Quarter Results Simply Wall St.
May-09-20 01:31PM	Amicus Therapeutics Inc (FOLD) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
07:00AM	Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders GlobeNewswire
May-07-20 09:25AM	Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates GlobeNewswire
May-06-20 07:00AM	UPDATE Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting GlobeNewswire
May-05-20 07:00AM	Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting GlobeNewswire
Apr-30-20 12:33PM	Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-24-20 07:00AM	Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 GlobeNewswire +6.13%
Apr-13-20 08:42AM	Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? Simply Wall St.
Apr-01-20 11:30AM	Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue? Zacks
Mar-28-20 08:38PM	Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Mar-24-20 10:00AM	Edited Transcript of FOLD earnings conference call or presentation 2-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +7.93%
Mar-23-20 07:00AM	Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees GlobeNewswire
Mar-05-20 07:00AM	Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia GlobeNewswire
Mar-04-20 07:20AM	Amicus Therapeutics, Inc. Yearly Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St. +5.91%
Mar-03-20 02:20PM	Amicus set to unveil $25M global research and gene therapy center in University City (Photo gallery) American City Business Journals
09:38AM	Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass Zacks
Mar-02-20 08:25AM	Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates GlobeNewswire
Feb-26-20 07:00AM	Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference GlobeNewswire
Feb-24-20 12:30PM	Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 07:00AM	Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020 GlobeNewswire
Feb-17-20 07:43AM	Our Take On Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Salary Simply Wall St.
Feb-07-20 07:00AM	Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium 2020 GlobeNewswire
Jan-13-20 07:00AM	Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance GlobeNewswire -5.66%
Jan-10-20 11:43AM	2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD) Insider Monkey
Jan-09-20 07:00AM	Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance GlobeNewswire
Jan-08-20 10:04AM	Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease Zacks
Jan-07-20 07:00AM	Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease GlobeNewswire
Jan-06-20 06:32PM	Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Jan-03-20 09:41AM	Amicus Progresses on Pipeline Development Amid Competition Zacks
Jan-02-20 08:04AM	If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Three Years Ago, You Could Pocket A 73% Gain Today Simply Wall St.
Dec-11-19 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report? Zacks
Dec-05-19 10:53PM	Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early Insider Monkey -6.79%
Dec-04-19 09:28AM	Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue? Zacks
Nov-20-19 10:09AM	Co-working space takes aim at Lake Nona American City Business Journals
Nov-19-19 03:03PM	How to Find Cheap Buy-Ranked Stocks Trading Under $10 Zacks
Nov-18-19 09:24AM	Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? Simply Wall St.
Nov-12-19 09:52AM	Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat Zacks
09:33AM	Company News For Nov 12, 2019 Zacks
09:25AM	Done deal: Tavistock sells land to New Jersey biotech firm American City Business Journals
Nov-11-19 08:15AM	Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
Nov-08-19 12:47PM	Earnings Reports for the Week of Nov. 11-15 (DHI, NVDA, WMT) Kiplinger
Nov-07-19 11:41AM	Bet on This Biotech Before Earnings Schaeffer's Investment Research
11:15AM	Cronos (CRON) to Report Q3 Earnings: What's in the Cards? Zacks
10:32AM	Tilray (TLRY) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-05-19 11:50AM	CannTrust (CTST) to Report Q3 Earnings: What's in Store? Zacks
11:24AM	What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
11:13AM	Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards? Zacks
09:15AM	PCTEL (PCTI) Gears Up for Q3 Earnings: What's in Store? Zacks
Nov-04-19 11:42AM	What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
10:30AM	Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
07:13AM	CenturyLink (CTL) Gears Up for Q3 Earnings: What's in Store? Zacks
Oct-30-19 07:00AM	Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019 GlobeNewswire
Oct-24-19 04:52PM	Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)? Insider Monkey
07:00AM	Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society GlobeNewswire
Oct-10-19 07:30AM	Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day GlobeNewswire
Oct-03-19 08:33PM	Edited Transcript of FOLD earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.60%
08:09AM	Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? Simply Wall St.
Oct-02-19 07:00AM	Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society GlobeNewswire
Oct-01-19 07:00AM	Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019 GlobeNewswire
Sep-07-19 09:30AM	Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report? Zacks
Sep-04-19 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019 GlobeNewswire
Aug-19-19 09:35AM	Is Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Overpaid Relative To Its Peers? Simply Wall St.
Aug-12-19 10:59AM	Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-10-19 01:30AM	Amicus Therapeutics Inc (FOLD) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 09:25AM	Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM	Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
Aug-02-19 07:00AM	Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina GlobeNewswire -6.43%
Aug-01-19 10:33AM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
06:00AM	Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease GlobeNewswire
Jul-29-19 07:00AM	Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019 GlobeNewswire
Jul-22-19 01:07PM	New Jersey biotech firm to open Lake Nona office, lab American City Business Journals
Jul-04-19 01:39PM	If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Five Years Ago, You Could Pocket A 227% Gain Today Simply Wall St.
11:51AM	Why Amicus Therapeutics' Stock Perked Up in June Motley Fool
Jul-02-19 07:30AM	Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing GlobeNewswire
Jul-01-19 07:00AM	Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration GlobeNewswire
Jun-19-19 09:59PM	Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy? Insider Monkey
Jun-13-19 07:30AM	Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership GlobeNewswire
Jun-12-19 05:49PM	New Jersey biotech firm scales back Lake Nona plans American City Business Journals
08:44AM	2 Small Biotechs With Sagging Shares but Promising Prospects TheStreet.com
Jun-07-19 09:30AM	Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report? Zacks
Jun-05-19 11:25AM	Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 04:01PM	Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock GlobeNewswire +7.82%
Jun-03-19 07:00AM	Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences GlobeNewswire
May-31-19 07:34AM	The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga
May-30-19 09:00PM	Amicus Therapeutics Prices Underwritten Offering of Common Stock GlobeNewswire -9.79%
04:29PM	Why NIO, PVH, and Amicus Therapeutics Slumped Today Motley Fool
02:11PM	Here's Why Amicus Therapeutics Fell as Much as 15.6% Today Motley Fool
10:34AM	2 Ultra-High-Growth Biotech Stocks to Buy Now Motley Fool
07:33AM	The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug Benzinga
May-29-19 04:14PM	Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire
11:36AM	Amicus, Penn expand gene therapy collaboration in a big way American City Business Journals
06:30AM	Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration GlobeNewswire
May-13-19 05:00PM	Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors GlobeNewswire -5.18%

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	Chief Operating Officer	May 26	Option Exercise	6.06	2,500	15,150	357,855	May 28 05:20 PM
Campbell Bradley L	Chief Operating Officer	May 26	Sale	13.01	2,500	32,525	355,355	May 28 05:20 PM
Crowley John F	Chairman & CEO	May 15	Option Exercise	5.13	20,000	102,600	959,941	May 19 07:52 PM
Crowley John F	Chairman & CEO	May 15	Sale	11.44	20,000	228,796	939,941	May 19 07:52 PM
Campbell Bradley L	Chief Operating Officer	May 01	Option Exercise	6.06	10,000	60,600	372,858	May 05 05:46 PM
Campbell Bradley L	Chief Operating Officer	May 01	Sale	11.33	17,503	198,239	355,355	May 05 05:46 PM
Crowley John F	Chairman & CEO	May 01	Sale	11.32	9,755	110,469	939,941	May 05 05:45 PM
MCGLYNN MARGARET G	Director	Apr 17	Option Exercise	2.81	10,000	28,100	32,064	Apr 20 04:57 PM
MCGLYNN MARGARET G	Director	Apr 17	Sale	11.00	10,000	110,000	22,064	Apr 20 04:57 PM
Crowley John F	Chairman & CEO	Apr 15	Option Exercise	5.13	20,000	102,600	969,696	Apr 17 07:46 PM
Crowley John F	Chairman & CEO	Apr 15	Sale	9.92	20,000	198,412	949,696	Apr 17 07:46 PM
Campbell Bradley L	Chief Operating Officer	Apr 07	Option Exercise	6.06	2,500	15,150	365,358	Apr 09 06:38 PM
Campbell Bradley L	Chief Operating Officer	Apr 07	Sale	10.12	2,500	25,300	362,858	Apr 09 06:38 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Option Exercise	6.06	7,500	45,450	363,014	Apr 03 06:40 PM
Crowley John F	Chairman & CEO	Apr 01	Sale	9.08	9,755	88,608	909,081	Apr 03 06:43 PM
Campbell Bradley L	Chief Operating Officer	Apr 01	Sale	9.09	15,003	136,310	348,011	Apr 03 06:40 PM
Crowley John F	Chairman & CEO	Mar 20	Option Exercise	5.13	20,000	102,600	938,836	Mar 24 06:40 PM
Crowley John F	Chairman & CEO	Mar 20	Sale	9.00	20,000	180,000	918,836	Mar 24 06:40 PM
Campbell Bradley L	Chief Operating Officer	Mar 05	Option Exercise	5.96	2,500	14,900	358,014	Mar 09 05:56 PM
Campbell Bradley L	Chief Operating Officer	Mar 05	Sale	10.01	2,500	25,025	355,514	Mar 09 05:56 PM
Campbell Bradley L	Chief Operating Officer	Mar 02	Option Exercise	5.96	7,500	44,700	370,517	Mar 04 06:53 PM
Crowley John F	Chairman & CEO	Mar 02	Sale	9.10	9,755	88,745	918,836	Mar 04 06:54 PM
Campbell Bradley L	Chief Operating Officer	Mar 02	Sale	9.09	15,003	136,445	355,514	Mar 04 06:53 PM
Crowley John F	Chairman & CEO	Feb 18	Option Exercise	5.13	20,000	102,600	948,591	Feb 20 04:44 PM
Crowley John F	Chairman & CEO	Feb 18	Sale	10.83	20,000	216,676	928,591	Feb 20 04:44 PM
Do Hung	Chief Science Officer	Feb 12	Option Exercise	6.08	53,100	322,601	574,255	Feb 14 04:19 PM
Do Hung	Chief Science Officer	Feb 12	Sale	11.01	63,356	697,340	510,899	Feb 14 04:19 PM
Campbell Bradley L	Chief Operating Officer	Feb 05	Option Exercise	5.96	2,500	14,900	365,517	Feb 07 05:19 PM
Campbell Bradley L	Chief Operating Officer	Feb 05	Sale	10.01	2,500	25,025	363,017	Feb 07 05:19 PM
Campbell Bradley L	Chief Operating Officer	Feb 03	Option Exercise	5.96	7,500	44,700	378,020	Feb 04 05:38 PM
Crowley John F	Chairman & CEO	Feb 03	Sale	8.91	9,754	86,882	928,591	Feb 04 05:36 PM
Campbell Bradley L	Chief Operating Officer	Feb 03	Sale	8.91	15,003	133,626	363,017	Feb 04 05:38 PM
Crowley John F	Chairman & CEO	Jan 15	Option Exercise	5.13	20,000	102,600	1,058,339	Jan 17 05:37 PM
Rosenberg Ellen	Chief Legal Officer	Jan 15	Sale	10.35	22,100	228,642	185,350	Jan 17 05:39 PM
Campbell Bradley L	Chief Operating Officer	Jan 15	Sale	10.35	5,064	52,388	370,520	Jan 17 05:38 PM
Barth Jay	Chief Medical Officer	Jan 15	Sale	10.35	20,720	214,359	156,473	Jan 17 05:39 PM
Crowley John F	Chairman & CEO	Jan 15	Sale	10.35	100,000	1,034,790	958,339	Jan 17 05:37 PM
Quimi Daphne	Chief Financial Officer	Jan 09	Option Exercise	2.72	11,022	30,007	177,991	Jan 10 05:27 PM
Campbell Bradley L	Chief Operating Officer	Jan 09	Option Exercise	5.96	2,500	14,900	347,695	Jan 10 05:28 PM
MCGLYNN MARGARET G	Director	Jan 09	Option Exercise	3.32	20,000	66,400	42,064	Jan 10 05:34 PM
MCGLYNN MARGARET G	Director	Jan 09	Sale	10.00	20,000	200,000	22,064	Jan 10 05:34 PM
Campbell Bradley L	Chief Operating Officer	Jan 09	Sale	10.01	2,500	25,025	345,195	Jan 10 05:28 PM
Quimi Daphne	Chief Financial Officer	Jan 09	Sale	9.93	15,000	148,952	166,969	Jan 10 05:27 PM
Barth Jay	Chief Medical Officer	Jan 07	Sale	9.36	9,938	92,980	156,473	Jan 08 07:46 PM
Barth Jay	Chief Medical Officer	Jan 06	Sale	9.28	6,836	63,415	166,411	Jan 08 07:46 PM
Campbell Bradley L	Chief Operating Officer	Jan 02	Option Exercise	5.96	7,500	44,700	366,640	Jan 03 05:17 PM
Barth Jay	Chief Medical Officer	Jan 02	Sale	9.55	9,753	93,173	189,522	Jan 03 05:21 PM
Rosenberg Ellen	Chief Legal Officer	Jan 02	Sale	9.56	10,448	99,884	201,332	Jan 03 05:20 PM
Campbell Bradley L	Chief Operating Officer	Jan 02	Sale	9.58	22,127	211,889	359,140	Jan 03 05:17 PM
Crowley John F	Chairman & CEO	Dec 16	Option Exercise	5.13	20,000	102,600	755,694	Dec 18 07:42 PM
Crowley John F	Chairman & CEO	Dec 16	Sale	9.55	20,000	191,014	735,694	Dec 18 07:42 PM
Crowley John F	Chairman & CEO	Dec 02	Option Exercise	3.82	20,000	76,400	755,694	Dec 04 05:17 PM
Crowley John F	Chairman & CEO	Dec 02	Sale	10.38	20,000	207,618	735,694	Dec 04 05:17 PM
Crowley John F	Chairman & CEO	Nov 25	Option Exercise	3.82	40,000	152,800	775,694	Nov 27 05:03 PM
Crowley John F	Chairman & CEO	Nov 25	Sale	10.01	40,000	400,204	735,694	Nov 27 05:03 PM
Crowley John F	Chairman & CEO	Nov 15	Option Exercise	5.13	20,000	102,600	755,694	Nov 19 06:17 PM
Crowley John F	Chairman & CEO	Nov 15	Sale	9.52	20,000	190,390	735,694	Nov 19 06:17 PM
Crowley John F	Chairman & CEO	Nov 08	Option Exercise	5.13	20,000	102,600	755,694	Nov 12 05:50 PM
Crowley John F	Chairman & CEO	Nov 08	Sale	9.02	20,000	180,414	735,694	Nov 12 05:50 PM
Crowley John F	Chairman & CEO	Oct 11	Sale	8.01	14,500	116,073	735,694	Oct 15 05:03 PM
Crowley John F	Chairman & CEO	Sep 11	Option Exercise	3.82	20,000	76,400	770,194	Sep 13 05:09 PM
Crowley John F	Chairman & CEO	Sep 11	Sale	10.05	20,000	201,030	750,194	Sep 13 05:09 PM
WHITMAN BURKE W	Director	Aug 23	Buy	10.07	4,945	49,796	21,612	Aug 27 07:59 PM
Crowley John F	Chairman & CEO	Aug 01	Option Exercise	3.82	20,000	76,400	770,194	Aug 02 04:40 PM
Crowley John F	Chairman & CEO	Aug 01	Sale	12.54	20,000	250,736	750,194	Aug 02 04:40 PM
Crowley John F	Chairman & CEO	Jul 01	Option Exercise	3.82	20,000	76,400	770,194	Jul 02 05:18 PM
Crowley John F	Chairman & CEO	Jul 01	Sale	12.47	20,000	249,462	750,194	Jul 02 05:18 PM
RAAB MICHAEL	Director	Jun 03	Option Exercise	7.15	5,000	35,750	13,895	Jun 04 04:35 PM
Crowley John F	Chairman & CEO	Jun 03	Option Exercise	3.82	20,000	76,400	770,399	Jun 04 04:34 PM
Crowley John F	Chairman & CEO	Jun 03	Sale	11.15	20,000	223,072	750,399	Jun 04 04:34 PM
RAAB MICHAEL	Director	Jun 03	Sale	11.16	5,000	55,776	8,895	Jun 04 04:35 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience